tirzepatide cvot 🫀 EASD 2025: (SURPASS-CVOT) Dulaglutide head-to-head showdown: ✓ Noninferior for MACE ✓ 16% ↓ all-cause mortality ✓ Superior in A1C & weight loss Tirzepatide confirms its broad cardiometabolic edge. #EASD2025 # Tirzepatide #GLP1 Frontiers | Tirzepatide's innovative applications

GIP receptor activation may explain why Tirzepatide users often report less nausea than Semaglutide users despite superior weight loss results

If they arent achieving results, then we may use FDA-approved medically assisted weight loss treatments. While the brand name Ozempic or oral semaglutide Rybelsus arent FDA-approved for weight loss, an injectable semaglutide is approved under the name Wegovy

Other drugmakers including Amgen, Boehringer Ingelheim, and Novo Nordisk are working on multi-receptor candidates of their own, which suggests that triple- and even four-receptor designs are likely the future of obesity pharmacology.[4] What makes retatrutide different from drugs already on the market is that it works on three of your body's natural appetite and metabolism signals at the same time

Conversely, others choose morning administration to monitor for adverse effects during waking hours when they can implement management strategies

Event: Novo Nordisk Files Lawsuits Over Compounded Ozempic Date: April 1, 2024 Notes: Novo Nordisk is actively pursuing lawsuits against pharmacies that sell compounded semaglutide